RxDoctor Payments Data

Lukasz Cerbin, MD

Clinical Cardiac Electrophysiology · Aurora, CONPI 1851780530

Payments from drug & device makers

What this record shows

The money is spread across several categories — grants (36.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Boston Scientific at 41.2% of the total. Reporting peaked in 2022 at $8,397 and has fallen 61.4% since, to $3,244 in 2025.

$17,977in general payments, 2019–2025

Across 148 payments — averaging $121.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$7K
  • Medtronic$6K
  • Abbott$3K
  • Biosense Webster, Inc.$709
  • Biotronik Inc.$119
  • AstraZeneca$94
  • plus $93 from 2 others

What the payments were for

  • Grants$6,59937%
  • Travel & lodging$4,67226%
  • Food & beverage$5,83532%
  • Education$8715%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,977 in reported general payments places this provider in the 55th percentile of 66 clinical cardiac electrophysiology providers in Colorado.

See all clinical cardiac electrophysiology providers in Colorado

Medicare billing

Part B allowed, 2024
$96,931
Medicare patients
354
Services billed
773

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban73$106,814
XareltoRivaroxaban18$23,045
JardianceEmpagliflozin13$15,012
Flecainide Acetate25$3,009
Metoprolol Succinate69$1,162
Amiodarone Hcl16$569
Metoprolol Tartrate13$117
Furosemide11$53

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$75$106,81473 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 66 clinical cardiac electrophysiology providers in Colorado.

Other clinical cardiac electrophysiology in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →